--- title: "Sionna Therapeutics (SION) news: IPO and offering" url: "https://aibio.space/companies/sionna-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SION IPO and offering news: Sionna Therapeutics prices IPO of 10,588,233 shares at $18.00. Sionna Therapeutics, Inc. (NASDAQ: SION), United States." --- SION Sionna Therapeutics, Inc. NASDAQ · United States # Sionna Therapeutics (SION) news SION IPO and offering news Distress · 2026-09-14 ## [Sionna Therapeutics cuts about 46% of workforce, sees cash into second half of 2029](https://aibio.space/news/sionna-therapeutics-cuts-about-46-percent-workforce-sees-cash-second/) Sionna Therapeutics said it will cut about 46% of its workforce, expects about $6.4 million in restructuring charges, and expects its cash to last into the second half of 2029. The cuts follow a missed key endpoint for SION-719 in a Phase 2a trial. ## Latest Sionna Therapeutics news 1. 2026-03-02 Financings [Sionna Therapeutics files automatic shelf with $250,000,000 ATM sales agreement](https://aibio.space/news/sionna-therapeutics-files-automatic-shelf-250-000-000-atm-sales/) Sionna Therapeutics signed a sales agreement with Leerink Partners LLC on March 2, 2026 for up to $250,000,000 of common stock sold at the market. Leerink's commission is up to 3.0% of the gross sales price per share. 2. 2025-02-07 Financings [Sionna Therapeutics prices IPO of 10,588,233 shares at $18.00](https://aibio.space/news/sionna-therapeutics-prices-ipo-10-588-233-shares-18-00/) The offering totals $190,588,194, and the stock is approved to list on Nasdaq under SION. Proceeds to the company are $177,247,020 before expenses. 3. 2025-01-17 Financings [Sionna Therapeutics files for IPO of common stock, seeks Nasdaq listing as SION](https://aibio.space/news/sionna-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-sion/) Sionna Therapeutics filed a preliminary S-1 on January 17, 2025 for an IPO of common stock on the Nasdaq Global Market under SION. The filing leaves the share count, price range and net proceeds blank, and lists Goldman Sachs & Co. LLC, TD Cowen, Stifel and Guggenheim Securities as underwriters without marking a lead. ## Sionna Therapeutics at a glance - **Ticker**: SION - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $63.3 million ### Related companies - [Zenas BioPharma](https://aibio.space/companies/zenas-biopharma/) NASDAQ: ZBIO - [BioMarin Pharmaceutical](https://aibio.space/companies/biomarin-pharmaceutical/) NASDAQ: BMRN - [Immunovant](https://aibio.space/companies/immunovant/) NASDAQ: IMVT - [MBX Biosciences](https://aibio.space/companies/mbx-biosciences/) NASDAQ: MBX - [Greenwich LifeSciences](https://aibio.space/companies/greenwich-lifesciences/) NASDAQ: GLSI - [Neurogene](https://aibio.space/companies/neurogene/) NASDAQ: NGNE - [Replimune Group](https://aibio.space/companies/replimune/) NASDAQ: REPL - [BridgeBio Pharma](https://aibio.space/companies/bridgebio-pharma/) NASDAQ: BBIO ### Also on NASDAQ - [STAAR SURGICAL CO](https://aibio.space/companies/staar-surgical/) STAA - [Valion Bio](https://aibio.space/companies/valion-bio/) VBIO - [Clene](https://aibio.space/companies/clene/) CLNN - [Lifeward](https://aibio.space/companies/lifeward/) LFWD - [LB Pharmaceuticals](https://aibio.space/companies/lb-pharmaceuticals/) LBRX - [BIOHARVEST SCIENCES INC.](https://aibio.space/companies/bioharvest-sciences/) BHST ## Sionna Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$60.3 million](https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/) | [$57.3 million](https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/) | | Net income (loss) | [-$75.3 million](https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/) | [-$61.7 million](https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/) | | Cash from operations | [-$66.3 million](https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/) | [-$52.8 million](https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/) | | Cash and equivalents | [$58.5 million](https://www.sec.gov/Archives/edgar/data/2036042/000162828026053839/) | [$37.8 million](https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $63.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Sionna Therapeutics When did Sionna Therapeutics go public? Our latest story on this, dated Feb 7, 2025: "Sionna Therapeutics prices IPO of 10,588,233 shares at $18.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sionna-therapeutics-prices-ipo-10-588-233-shares-18-00/). Has Sionna Therapeutics raised money recently? Our latest story on this, dated Mar 2, 2026: "Sionna Therapeutics files automatic shelf with $250,000,000 ATM sales agreement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sionna-therapeutics-files-automatic-shelf-250-000-000-atm-sales/). What is the ticker symbol of Sionna Therapeutics? Sionna Therapeutics, Inc. trades under the ticker SION on NASDAQ. Where is Sionna Therapeutics listed? Sionna Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Sionna Therapeutics? The SEC Central Index Key (CIK) for Sionna Therapeutics, Inc. is 2036042. Its filings are on SEC EDGAR. How many shares does Sionna Therapeutics have outstanding? 45,212,399 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Sionna Therapeutics listed under? Our directory records Sionna Therapeutics, Inc. under United States. What does Sionna Therapeutics do? Our directory classifies Sionna Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Sionna Therapeutics? The ISIN recorded for Sionna Therapeutics, Inc. is US8294011080. Does aibio.space cover Sionna Therapeutics? aibio.space lists Sionna Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Sionna Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Sionna Therapeutics profitable? Sionna Therapeutics, Inc. reported a net loss of $75.3 million for the fiscal year ended Dec 31, 2025, and used $66.3 million of cash in operations, per its annual report to the SEC. How much does Sionna Therapeutics spend on research and development? $60.3 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Sionna Therapeutics have? $63.3 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Sionna Therapeutics (SION) stock news? Our latest story on Sionna Therapeutics, dated Sep 14, 2026: "Sionna Therapeutics cuts about 46% of workforce, sees cash into second half of 2029". Sionna Therapeutics said it will cut about 46% of its workforce, expects about $6.4 million in restructuring charges, and expects its cash to last into the second half of 2029. The cuts follow a missed key endpoint for SION-719 in a Phase 2a trial. [Source](https://aibio.space/news/sionna-therapeutics-cuts-about-46-percent-workforce-sees-cash-second/). ## Investor discussion: Sionna Therapeutics Members talk about Sionna Therapeutics (SION). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Sionna Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-09-14 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2036042/000119312526390577/d148638dex991.htm) 2. 2026-03-02 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/2036042/000119312526084308/d16683ds3asr.htm) 3. 2025-02-07 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/2036042/000119312525022709/d882384d424b4.htm) 4. 2025-01-17 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/2036042/000119312525008474/d882384ds1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SION on TradingView](https://www.tradingview.com/symbols/NASDAQ-SION/). ## SEC filings and registration - **SEC name**: Sionna Therapeutics, Inc. - **CIK**: 2036042 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SION (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 21 HICKORY DRIVE, SUITE 500, WALTHAM, MA, 02451 - **Phone**: 617-819-2020 - **Shares outstanding**: 45,212,399 as of 2026-07-31 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/2036042/000119312526390577/d148638d8k.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/2036042/000119312526341230/d135438d8k.htm) filed 2026-08-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/2036042/000162828026053839/sionna-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/2036042/000162828026053832/sion-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/2036042/000162828026044263/sion-20260617.htm) filed 2026-06-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/2036042/000162828026033876/sionna-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/2036042/000162828026033870/sion-20260512.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/2036042/000162828026027489/sion-20260427.htm) filed 2026-04-27 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002036042), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Sionna Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SION, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Sionna Therapeutics, Inc. - **Ticker**: SION - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US8294011080 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SION/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/sionna-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sionna Therapeutics (SION) news: IPO and offering", 2026-10-31, https://aibio.space/companies/sionna-therapeutics/